Potential use of TNF-α inhibitors in systemic sclerosis

Immunotherapy

Volumn 6, Issue 3, 2014, Pages 283-289

  Murdaca, Giuseppe ^a   Spanò, Francesca ^a   Contatore, Miriam ^a   Guastalla, Andrea ^a   Puppo, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

systemic sclerosis; TNF inhibitor

Indexed keywords

ADALIMUMAB; AUTOANTIBODY; CALCIUM ANTAGONIST; ETANERCEPT; INDUCIBLE NITRIC OXIDE SYNTHASE; INFLIXIMAB; METHOTREXATE; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULOTROPIN; VASODILATOR AGENT; ANTIRHEUMATIC AGENT; CERTOLIZUMAB PEGOL; GOLIMUMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANGIONEUROTIC EDEMA; ANTIBODY TITER; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; DISABILITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIUM; HUMAN; IMMUNOTHERAPY; INFLAMMATION; INJECTION SITE REACTION; LIPID ANALYSIS; MORNING STIFFNESS; OPPORTUNISTIC INFECTION; PHYSICIAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK REDUCTION; SCLERODERMA; SERUM; SYSTEMIC SCLEROSIS; THROMBOCYTOPENIA; TUBERCULOSIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS; BIOSYNTHESIS; COMPLICATION; DRUG COMBINATION; DRUG SCREENING; FORECASTING; HYPERTENSION, PULMONARY; IMMUNOLOGY; LATENT TUBERCULOSIS; OPPORTUNISTIC INFECTIONS; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; VASCULAR ENDOTHELIUM;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIRHEUMATIC AGENTS; ARTHRITIS; DRUG EVALUATION; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; FORECASTING; HUMANS; HYPERTENSION, PULMONARY; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LATENT TUBERCULOSIS; OPPORTUNISTIC INFECTIONS; POLYETHYLENE GLYCOLS; PULMONARY FIBROSIS; RECEPTORS, TUMOR NECROSIS FACTOR; SCLERODERMA, SYSTEMIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84899047993     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.173     Document Type: Article

References (45)

1. Gazi H, Pope JE, Clements P et al. Outcome measurements in scleroderma: Results from a delphi exercise. J. Rheumatol. 34, 501-599 (2007).
2. Thompson AE, Pope JE. Increased prevalence of scleroderma in southwestern Ontario: A cluster analysis. J. Rheumatol. 29, 1867-1873 (2002).
3. Murdaca G, Colombo BM, Cagnati P, Gulli R, Spanò F, Puppo F. Update upon efficacy and safety of TNF-α inhibitors. Expert Opin. Drug Saf. 11(1), 1-5 (2012).
4. Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: A new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events. Autoimmun. Rev. 11(1), 56-60 (2011).
5. Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: An update on old and recent indications. Drugs Today (Barc.) 47(4), 277-288 (2011).
6. Murdaca G, Colombo BM, Puppo F. Anti-TNF-Alpha inhibitors: A new therapeutic approach for inflammatory immune-mediated diseases: An update upon efficacy and adverse events. Int. J. Immunopathol. Pharmacol. 22(3), 557-565 (2009).
7. Murdaca G, Colombo BM, Barabino G, Caiti M, Cagnati P, Puppo F. Anti-Tumor necrosis factor-α treatment with infliximab for disseminated granuloma annulare. Am. J. Clin. Dermatol. 11(6), 437-439 (2010).
8. Puppo F, Murdaca G, Ghio M, Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun. Rev. 4(8), 537-541 (2005).
9. Hasegawa M, Fujimoto M, Kikuchi K, Takehara K. Elevated serum tumor necrosis factor-Alpha levels in patients with systemic sclerosis: Association with pulmonary fibrosis. J. Rheumatol. 24(4), 663-665 (1997).
10. Murdaca G, Colombo BM, Cagnati P et al. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 224(2), 309-317 (2012).
11. Ciprandi G, Murdaca G, Colombo BM, De Amici M, Marseglia GL. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum. Immunol. 69(8), 510-512 (2008).
12. Ciprandi G, Colombo BM, Murdaca G, De Amici M. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy 63(7), 945-946 (2008).
13. Murdaca G, Span? F, Cagnati P, Puppo F. Free radicals and endothelial dysfunction: Potential positive effects of TNF-α inhibitors. Redox Rep. 18(3), 95-99 (2013).
14. Truchetet ME, Brembilla NC, Montanari E et al. Interleukin 17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. Arthritis Rheum. 65(5), 1347-1356 (2013).
15. Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern. Emerg. Med. 6(6), 487-495 (2011).
16. Kowal-Bielecka O, Landewé R, Avouac J et al. EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann. Rheum. Dis. 68(5), 620-628 (2009).
17. Chang J, Girgis L. Clinical use of anti-TNF-Alpha biological agents-A guide for GPs. Aust. Fam. Physician 36, 1035-1038 (2007).
18. Murdaca G, Spanò F, Puppo F. Use of leflunomide plus TNF-α inhibitors in rheumatoid arthritis. Expert Opin. Drug Saf. 12(6), 801-804 (2013).
19. Murdaca G, Colombo BM, Contini P, Puppo F. Determination of lymphotoxin-Alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J. Interferon Cytokine Res. 32(6), 277-279 (2012).
20. Murdaca G, Span? F, Puppo F. Selective TNF-α inhibitorinduced injection site reactions. Expert Opin. Drug Saf. 12(2), 187-193 (2013).
21. Peschon JJ, Torrance DS, Stocking KL et al. TNF receptordeficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J. Immunol. 160, 943-952 (1998).
22. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol. 168, 4620-4627 (2002).
23. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat. Clin. Pract. Rheumatol. 2, 602-610 (2006).
24. Horiki T, Moriuchi J, Takaya M et al. The coexistence of systemic sclerosis and rheumatoid arthritis in five patients. Clinical and immunogenetic features suggest a distinct entity. Arthritis Rheum. 39(1), 152-156 (1996).
25. Zimmermann C, Steiner G, Skriner K, Hassfeld W, Petera P, Smolen JS. The concurrence of rheumatoid arthritis and limited systemic sclerosis: Clinical and serologic characteristics of an overlap syndrome. Arthritis Rheum. 41(11), 1938-1945 (1998).
26. Phumethum V, Jamal S, Johnson SR. Biologic therapy for systemic sclerosis: A systematic review. J. Rheumatol. 38(2), 289-296 (2011).
27. Omair MA, Phumethum V, Johnson SR. Long-Term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis. Clin. Exp. Rheumatol. 30(2 Suppl. 71), S55-S59 (2012).
28. Denton CP, Engelhart M, Tvede N et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann. Rheum. Dis. 68(9), 1433-1439 (2009).
29. Bosello S, De Santis M, Tolusso B, Zoli A, Ferraccioli G. Tumor necrosis factor-Alpha inhibitor therapy in erosive polyarthritis secondary to systemic sclerosis. Ann. Intern. Med. 2005 143(12), 918-920 (2005).
30. Lam GK, Hummers LK, Woods A, Wigley FM. Efficacy and safety of etanercept in the treatment of sclerodermaassociated joint disease. J. Rheumatol. 34(7), 1636-1637 (2007).
31. Bargagli E, Galeazzi M, Bellisai F, Volterrani L, Rottoli P. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 75(3), 346-349 (2008).
32. Stewart FA, Gavino AC, Elewski BE. New side effect of TNF-Alpha inhibitors: Morphea. Skinmed 11(1), 59-60 (2013).
33. Ramos-Casals M, Perez-Alvarez R , Diaz-Lagares C, Cuadrado MJ, Khamashta MA; BIOGEAS Study Group. Autoimmune diseases induced by biological agents: A double-edged sword? Autoimmun. Rev. 9(3), 188-193 (2010).
34. Hamaguchi M, Kawahito Y, Ishino H, Yoshida M, Yoshikawa T. A case report of tumor necrosis factor-Alpha antibody-induced thrombocytopenia associated with emerging IgM anticardiolipin antibody in patients with scleroderma overlap/rheumatoid arthritis. Clin. Rheumatol. 26(6), 988-990 (2007).
35. Azevedo VF, Silva MB, Marinello DK, Santos FD, Silva GB. Leukopenia and thrombocytopenia induced by etanercept: Two case reports and literature review. Rev. Bras. Reumatol. 52(1), 110-112 (2012).
36. Chen M, Holland MJ, Mir MR et al. Frequency of thrombocytopenia in psoriasis patients treated with tumor necrosis factor-A inhibitors. J. Drugs Dermatol. 10(3), 280-284 (2011).
37. Leger S, Etienne M, Duval-Modeste AB, Roussel A, Caron F, Thiberville L. Interstitial pneumonia after infliximab therapy for psoriasis. Ann. Dermatol. Venereol. 138(6-7),499-503 (2011).
38. Dascalu C, Mrejen-Shakin K, Bandagi S. Adalimumabinduced acute pneumonitis in a patient with rheumatoid arthritis. J. Clin. Rheumatol. 16(4), 172-174 (2010).
39. Lindsay K, Melsom R, Jacob BK, Mestry N. Acute progression of interstitial lung disease: A complication of etanercept particularly in the presence of rheumatoid lung and methotrexate treatment. Rheumatology (Oxford) 45(8), 1048-1049 (2006).
40. Colombo BM, Cacciapaglia F, Puntoni M et al. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: Role of vascular endothelial growth factor (VEGATS Study). Autoimmun. Rev. 8(4), 309-315 (2009).
41. Colombo BM, Murdaca G, Caiti M et al. Intima-media thickness: A marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann. NY Acad. Sci. 1108, 121-126 (2007).
42. El Chami H, Hassoun PM. Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog. Cardiovasc. Dis. 55(2), 218-228 (2012).
43. Szekanecz Z, Kerekes G, Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat. Rev. Rheumatol. 5(12), 677-684 (2009).
44. Arenas IA, Armstrong SJ, Xu Y, Davidge ST. Chronic tumor necrosis factor-Alpha inhibition enhances NO modulation of vascular function in estrogen-deficient rats. Hypertension 46(1), 76-81 (2005).
45. Murdaca G, Spanò F, Miglino M, Puppo F. Effects of TNF-α inhibitors upon the mechanisms of action of VEGF. Immunotherapy 5(2), 113-115 (2013).